News

New analysis of 2304 patients shows CD19 CAR T-cell therapy efficacy is consistent across races, with outcomes driven by tumor burden and ECOG status.

Explore the top regulatory actions from the FDA in oncology this past month.

The oral FGFR2 inhibitor lirafugratinib is being reviewed by the FDA for the second-line treatment of cholangiocarcinoma harboring FGFR2 alternations.

ZW191 is engineered to bind to FRα, a cell-surface protein with high expression across several tumor types.

Young US cancer survivors face outsized food, housing and transport insecurity; Medicaid expansion and targeted SDOH screening may improve survivorship.

A retrospective analysis showed 2-year survival outcomes of over 13,000 patients receiving allogeneic hematopoietic cell transplants by donor source.

This week in oncology: FDA approves relacorilant for ovarian cancer, clinical data for lung and GI cancers, and a faster thawing method for bladder cancer.

Final results from the phase 2 OVATION 2 trial show that adding IMNN-001 to standard chemotherapy significantly improves overall survival in newly diagnosed advanced ovarian cancer.

Phase 2 TBCRC049 trial results show tucatinib triplet therapy improves survival in HER2+ breast cancer patients with leptomeningeal metastasis.

The ASTEROID trial shows adding durvalumab to SBRT significantly cuts tumor progression in early-stage NSCLC, though OS and DFS benefits remain uncertain.

The first patient recieved the novel investigational molecular glue degrader cemsidomide plus elranatamab for multiple myeloma.

Transdermal estradiol offers fewer hot flashes and lower fracture rates, but higher rates of gynecomastia, as it meets the noninferiority bar against LHRH agonists.

Experts review a stage IV NSCLC case, debating whether to delay treatment while awaiting PD-L1 results to ensure a more precise, tailored therapy plan.

A wave of innovations across antibody-drug conjugates, synergistic combinations, and expanding biomarkers is transforming the genitourinary cancer landscape from metastatic rescue toward curative, earlier-line paradigms.

Phase 2b data show RAD101 amino acid PET hits 90% concordance, helping distinguish brain metastasis recurrence from pseudoprogression and necrosis.

Second-line axi-cel CAR T boosts quality of life in relapsed large B-cell lymphoma, with early dip then lasting recovery for older patients.

FDA backs pivotal phase 3 plan for VCN-01 plus chemo in metastatic pancreatic cancer, building on phase 2 VIRAGE trial success.

FDA pushes LNTH-2501 decision to June 2026 for manufacturing review.

FDA fast tracks TRI-611, an ALK molecular glue degrader for refractory ALK+ NSCLC. Phase 1/2 trial targets resistance after 2 or more TKIs.

Use of the ProSense Cryoablation System in patients with kidney cancer resulted in an 83.9% recurrence-free rate among 112 patients in the ICESECRET clinical trial (NCT02399124).

Phase 2 interim safety data presented at EBMT 2026 annual meeting suggest no additive toxicity with the novel combination chronic GVHD regimen.

New first-line ES-SCLC data show iza-bren plus serplulimab drives 88% responses and manageable safety, setting up phase 3 trials.

The proposed biosimilar demonstrated clinical equivalence to the reference product in overall response rate at 18 weeks, with a comparable safety profile, supporting regulatory submissions.

Phase 1 data show setidegrasib degrades KRAS G12D, delivering durable NSCLC responses with manageable safety and biomarker-linked benefit as phase 3 plans advance.

Venetoclax plus ibrutinib shows deep, durable responses in marginal zone lymphoma, with promising 5-year PFS and manageable safety in phase 2 AIM study.

FDA approves relacorilant for platinum-resistant ovarian cancer, showing significant survival benefits without added safety risks in clinical trials.

The FDA approved a label change for nadofaragene firadenovec-vncg (Adstiladrin) in non–muscle-invasive bladder cancer to improve preparation time.

Mohamed K. Mohamed, MD, PhD, discusses how CIM disrupts treatment, burdens patients, and why a proactive management approach is critical in SCLC care.